September, 11, 2015 – Japanese medical vendor Nipro Corp. signed a definitive agreement to acquire Infraredx Inc., maker of a combined intravascular ultrasound (IVUS) integrated with near infrared spectroscopy (NIRS) for the detection of lipid-core plaque (LCP) coronary plaque.
Nipro offers medical products and technologies in a wide range of fields, including artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, pharmaceuticals and medical glass products. The agreement combines Nipro's strong global cardiovascular portfolio and resources along with Infraredx’s industry expertise in NIRS and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States.
The company plans to continue Infraredx’s strategic plans to continue clinical testing of NIRS as an advanced imaging tool required to predict heart attacks and shift from reactive treatment to proactive care of coronary artery disease.
“By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally,” said Jason Bottiglieri, president and CEO of Infraredx. “We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease.”
The acquisition, which is subject to certain conditions, is expected to close in October 2015.
For more information: www.infraredx.com
May 13, 2026 
